<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; secretary</title>
	<atom:link href="http://www.tapanray.in/tag/secretary/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Declining MR Access to Doctors Prompts Increased Digital Engagement</title>
		<link>http://www.tapanray.in/declining-mr-access-to-doctors-prompts-increased-digital-engagement/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=declining-mr-access-to-doctors-prompts-increased-digital-engagement</link>
		<comments>http://www.tapanray.in/declining-mr-access-to-doctors-prompts-increased-digital-engagement/#comments</comments>
		<pubDate>Sun, 02 Oct 2016 23:58:07 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Aceess]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[channels]]></category>
		<category><![CDATA[Declining]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[joint]]></category>
		<category><![CDATA[mandatory]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[of pharmaceuticals]]></category>
		<category><![CDATA[Pant]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[pfizerline]]></category>
		<category><![CDATA[Physician]]></category>
		<category><![CDATA[platforms]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[secretary]]></category>
		<category><![CDATA[Sudhanshu]]></category>
		<category><![CDATA[Sunshine]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7850</guid>
		<description><![CDATA[The trigger point for a disruptive change in the pharma marketing playbook now seems to be not just on the horizon, but could soon move to a countdown stage, in India. On Friday, September 16, 2016, at a seminar on &#8230; <a href="http://www.tapanray.in/declining-mr-access-to-doctors-prompts-increased-digital-engagement/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/declining-mr-access-to-doctors-prompts-increased-digital-engagement/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>&#8216;Indian Drug Control World’s Weakest: Pharma Trade Bodies Working At Cross Purposes&#8217;</title>
		<link>http://www.tapanray.in/indian-drug-control-worlds-weakest-pharma-trade-bodies-working-at-cross-purposes/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indian-drug-control-worlds-weakest-pharma-trade-bodies-working-at-cross-purposes</link>
		<comments>http://www.tapanray.in/indian-drug-control-worlds-weakest-pharma-trade-bodies-working-at-cross-purposes/#comments</comments>
		<pubDate>Mon, 25 Apr 2016 00:00:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[associations]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[bodies]]></category>
		<category><![CDATA[center]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Corruption]]></category>
		<category><![CDATA[cross-purposes]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Editorial]]></category>
		<category><![CDATA[Edmund]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[mandatory]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Ministers]]></category>
		<category><![CDATA[Office]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PMO]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[PTI]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[Safra]]></category>
		<category><![CDATA[secretary]]></category>
		<category><![CDATA[Subburaj]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[Voluntary]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7612</guid>
		<description><![CDATA[&#8220;In the entire world, I think our drug control system probably is the weakest today. It needs to be strengthened,&#8221; said the Secretary of the Department of Pharmaceuticals (DoP) &#8211; V K Subburaj at an event in New-Delhi on April &#8230; <a href="http://www.tapanray.in/indian-drug-control-worlds-weakest-pharma-trade-bodies-working-at-cross-purposes/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indian-drug-control-worlds-weakest-pharma-trade-bodies-working-at-cross-purposes/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India’s China Dependence On API: A Time To Think ‘Outside The Box’</title>
		<link>http://www.tapanray.in/indias-china-dependence-on-api-a-time-to-think-outside-the-box/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indias-china-dependence-on-api-a-time-to-think-outside-the-box</link>
		<comments>http://www.tapanray.in/indias-china-dependence-on-api-a-time-to-think-outside-the-box/#comments</comments>
		<pubDate>Mon, 21 Sep 2015 00:00:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2015]]></category>
		<category><![CDATA[Active]]></category>
		<category><![CDATA[Advisor]]></category>
		<category><![CDATA[Ananth Kumar]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[ASSOCHAM]]></category>
		<category><![CDATA[bulk]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[dependence]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[hamied]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[ingredients]]></category>
		<category><![CDATA[Katoch]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[out of box]]></category>
		<category><![CDATA[outside]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[recommendations]]></category>
		<category><![CDATA[secretary]]></category>
		<category><![CDATA[Security]]></category>
		<category><![CDATA[Subburaj]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[year of API]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7086</guid>
		<description><![CDATA[The Department of Pharmaceuticals (DoP) has declared the Year 2015 as the Year of ‘Active Pharmaceutical Ingredient (API)’. Following it up on February 25, 2015, the Union Minister of Chemicals &#38; Fertilizers Ananth Kumar assured the Pharmaceutical Industry that appropriate &#8230; <a href="http://www.tapanray.in/indias-china-dependence-on-api-a-time-to-think-outside-the-box/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indias-china-dependence-on-api-a-time-to-think-outside-the-box/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Has Prime Minister Modi Conceded Ground To America On Patents Over Patients?</title>
		<link>http://www.tapanray.in/has-prime-minister-modi-conceded-ground-to-america-on-patents-over-patients/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=has-prime-minister-modi-conceded-ground-to-america-on-patents-over-patients</link>
		<comments>http://www.tapanray.in/has-prime-minister-modi-conceded-ground-to-america-on-patents-over-patients/#comments</comments>
		<pubDate>Mon, 06 Oct 2014 00:00:15 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Arvind]]></category>
		<category><![CDATA[Baker]]></category>
		<category><![CDATA[Brook]]></category>
		<category><![CDATA[Columbia]]></category>
		<category><![CDATA[Commerce]]></category>
		<category><![CDATA[conceded]]></category>
		<category><![CDATA[Forum]]></category>
		<category><![CDATA[ground. America]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Jamie]]></category>
		<category><![CDATA[Kher]]></category>
		<category><![CDATA[Love]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[Northeastern]]></category>
		<category><![CDATA[Obama]]></category>
		<category><![CDATA[Panagariya]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[President]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Rajeev]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[School]]></category>
		<category><![CDATA[secretary]]></category>
		<category><![CDATA[Special 301]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[TPF]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[University]]></category>
		<category><![CDATA[USTR]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6060</guid>
		<description><![CDATA[Unprecedented high profile engagement of the Indian Prime Minister with various interested groups during his recent visit to the United States under equally unprecedented media glare, has invited overwhelmingly more kudos than brickbats, from across the world. However, in the &#8230; <a href="http://www.tapanray.in/has-prime-minister-modi-conceded-ground-to-america-on-patents-over-patients/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/has-prime-minister-modi-conceded-ground-to-america-on-patents-over-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>“Make Global Pharma Responsible in Homeland for Objectionable Conduct in Clinical Trials Elsewhere”</title>
		<link>http://www.tapanray.in/make-global-pharma-responsible-in-homeland-for-objectionable-conduct-in-clinical-trials-elsewhere/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=make-global-pharma-responsible-in-homeland-for-objectionable-conduct-in-clinical-trials-elsewhere</link>
		<comments>http://www.tapanray.in/make-global-pharma-responsible-in-homeland-for-objectionable-conduct-in-clinical-trials-elsewhere/#comments</comments>
		<pubDate>Wed, 12 Feb 2014 01:30:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Azad]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Chaudhury]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[Conduct]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[CRO]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Desiraju]]></category>
		<category><![CDATA[experts]]></category>
		<category><![CDATA[Ghulam]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[ISCR]]></category>
		<category><![CDATA[keshav]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Nabi]]></category>
		<category><![CDATA[NGO]]></category>
		<category><![CDATA[objectionable]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[Ranjit]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roy]]></category>
		<category><![CDATA[secretary]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[US]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4988</guid>
		<description><![CDATA[In the context of his recent meeting with Commissioner Margaret A. Hamburg of US-FDA, the Drug Controller General of India (DCGI) reportedly expressed his concern to ‘The Economic Times’ on the ‘objectionable conduct’ of global pharma in new drug trials &#8230; <a href="http://www.tapanray.in/make-global-pharma-responsible-in-homeland-for-objectionable-conduct-in-clinical-trials-elsewhere/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/make-global-pharma-responsible-in-homeland-for-objectionable-conduct-in-clinical-trials-elsewhere/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
